ClinicalTrials.gg
RecruitingNCT04765137Updated Jul 13, 2026

Evaluate the Effect of Atorvastatin on Cerebrovascular Reactivity in Mild Cognitive Impairment (MCI)

A Phase 2 interventional study of Atorvastatin Oral Tablet in Mild Cognitive Impairment, sponsored by Johns Hopkins University. Recruiting at 1 site in United States. Open to participants aged 60 Years to 95 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by Johns Hopkins University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2021; still recruiting 5 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
60 Years to 95 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 34 studies in Cognitive Dysfunction by Johns Hopkins University — 13 open to participants now, 15 under way, 1 of them phase 3. Cognitive Dysfunction · Johns Hopkins University.

Planned enrollment
25th of 33
20 · median 52
Started
2021
with 3 others
Phase 2
6 of 34
2 open now
Primary completion
2027-07
later than 4 of 14 live
Registered
14th of 34
by date

Among the 34 studies in Cognitive Dysfunction by Johns Hopkins University, this one is the 25th largest by planned enrollment of the 33 interventional ones that give a count, is one of 4 that started in 2021, is one of 6 in phase 2, reaches primary completion later than 4 of the 14 other live ones, and was the 14th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

13 of the 34 studies in Cognitive Dysfunction by Johns Hopkins University are open now, in 1 country. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 60 Years to 95 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Cognitive Dysfunction by Johns Hopkins University, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effect of atorvastatin on brain vessel reactivity and with it on blood flow in people with mild cognitive impairment.

Read the detailed description

Participants are first being informed about potential benefits and risks of the study and are required to give written consent. After that participants will undergo detailed phone screen to determine eligibility for study entry. At week 0, participants who meet eligibility requirements will be prescribed atorvastatin (40 mg, once in the evening) in an open-label manner.

03

Conditions studied

  • Mild Cognitive Impairment

Keywords

  • Cerebral Vascular Reactivity
04

Who can participate

Ages eligible
60 Years to 95 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria are chosen to include participants with MCI, enriched for vascular risk factors:

  • MCI defined by Clinical Dementia Rating (CDR) of 0.5 or 1.0.
  • Memory, processing speed, executive function, language - cognitive scores > 1.5 standard deviations below age-education norms.
  • Not demented by history.
  • Not taking statins currently or in the last 6 months.
  • Cognitive/functional impairment not likely due to another neurological disease or delirium.

Exclusion Criteria:

  • Taking a statin currently or have taken a statin in the last 6 months.
  • to taking a statin.
  • Transplant patient taking cyclosporine.
  • Unable to undergo MRI procedures (such as having an implanted pacemaker or defibrillator or stimulator or having non MRI compatible metal).
  • Diagnosis of dementia by history.
  • Current diagnosis of substance abuse.
  • History of stroke or myocardial infarction in past 6 months.
  • History of .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Atorvastatin 40 mg

    Participants receive 40 mg atorvastatin orally daily in the evening.

    Drug: Atorvastatin Oral Tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Change of MRI whole brain cerebrovascular reactivity (wbCVR)

    MRI based CVR is a newer technique that measures dilatory function of the microvessels which have been shown to be superior to measurement of Cerebral blood flow (CBF) and have also been shown to be low in participants with MCI.

    Time frame: Baseline and 12 weeks

Secondary outcomes

  1. Change in plasma exosomes

    Endothelial-derived exosomes (EDE) reflect the neurochemistry of cerebrovascular endothelial cells, while neuronal-enriched extracellular vesicles (nEV) are associated with brain white matter hyperintensities.

    Time frame: Baseline and 12 weeks

  2. Change in cognitive function (global neurocognitive measure)

    Assessed by Global neurocognitive measure.

    Time frame: Baseline and 12 weeks

  3. Change in cognitive function (domain-specific neurocognitive measure)

    Assessed by Domain-specific neurocognitive measure.

    Time frame: Baseline and 12 weeks

07

Study locations

1 of 1 sites recruiting
  • Johns Hopkins University, Bayview Medical Center
    Baltimore, Maryland 21224, United States
    Recruiting
    • Samantha Horn · Contactshorn8@jhmi.edu · 410-550-9020
    • Ritu Agarwal · Contactragarw19@jhmi.edu · 410-550-9020
    • Paul Rosenberg, MD · Principal investigator
    • Sevil Yasar, MD, PhD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2021 (actual). Primary completion is estimated for Jul 2027, 74 months after the start.

Of 145 non-industry phase 2 interventional studies under Cognitive Dysfunction, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 64. This study's planned 74 months is above that.

Counting every sponsor, half of 187 studies reached it within 42 months; a quarter within 22 and three quarters within 62.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2021
First posted
Feb 21, 2021
StartActual
May 21, 2021
Primary completionEst.
Jul 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04765137
Collaborators
The Richman Family Precision Medicine Center of Excellence in Alzheimer Disease
Responsible party
Sponsor
First posted
Feb 21, 2021
Start date
May 21, 2021
Primary completion
Jul 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jul 13, 2026

Study contacts

Samantha Horn
Contact
shorn8@jhmi.edu
410-550-9020
Ritu Agarwal
Contact
ragarw19@jhmi.edu
410-550-9020
Paul Rosenberg, MD
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atorvastatin

Start the discussion